Between 2000 and 2015, deaths resulting from stroke, heart disease, and prostate cancer decreased, whereas deaths from AD increased 123%.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Recent Medicare claims perform reasonably well in identifying dementia; however, there are consistent differences in cases of dementia identified through claims than in rigorous cohort evaluations. 5 key findings →
Participants: 54 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Total cost of care in early stage AD (CDR-SB ≤ 4) was 16,448€ (95% CI 13,722-19,716) annually. 5 key findings →
Participants: 231 Evidence: low
Full summary, score breakdown and related studies → Original source
Mean BBC in FY 2014 was 0.32; mean total cost in FY 2015 was $35 425. 4 key findings →
Participants: 102 Evidence: low
Full summary, score breakdown and related studies → Original source
The costs of dementia fall on families, highlighting limited policy and work supports. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundSeveral monoclonal antibodies designed to slow cognitive and functional decline in individuals with early Alzheimer's disease (AD) have been recently approved. 5 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
49/100
Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Microglia are resident macrophages of the central nervous system that have key functions in its development, homeostasis and response to damage and infection. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Measurement using validated tools for resident and family satisfaction and health outcomes showed that culture change interventions or clusters of interventions had few negative impacts, but also seldom resulted in statistically significant improvement. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Comorbidity indices for patients with cognitive impairment increased during the 6-year study period, especially after the index. 5 key findings →
Participants: 2,711 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
49/100
In 2022, the overall prevalence of homebound beneficiaries was 22.0% (8.4% of beneficiaries were homebound, and 13.6% were semihomebound). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We found that a larger share of Hispanic Medicare residents that are admitted to nursing homes have ADRD compared with African American and White beneficiaries. 3 key findings →
Participants: 1,302,099 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
According to the National Institute on Aging (NIA), there are more than 70 associated genes or genetic areas associated with Alzheimer’s when 20 years ago, we knew of only four (Hodes, 2022). 5 key findings →
Design: longitudinal study Participants: 42 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Frailty and dementia are associated with poor health outcomes and increased health care utilization. 3 key findings →
Design: cohort study Participants: 1,132,367 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
By 2060, ADRD cases in China are projected to reach approximately 49.89 million, with the highest prevalence and economic burden concentrated in provinces such as Shandong, Sichuan, Jiangsu, Henan, and Guangdong. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
49/100
Of 164,508 eligible participants, 6605(4%) had cognitive testing scores consistent with MCI. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to examine the associations between nursing home (NH) quality and prevalence of newly admitted NH residents with Alzheimer's disease and related dementias (ADRD), and to assess the extent to which market-level wages for certified nursing assistants (CNAs) and state Medicaid behavioral and mental health add-on policy may influence such associations. 4 key findings →
Design: cohort study Participants: 2,777 Evidence: moderate
Full summary, score breakdown and related studies → Original source
49/100
PA policies varied substantially across private insurers in the US. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of low vision in the Medicare population was 994/100,000 and increased significantly with age, Black (1,854/100,000) or Hispanic (2,862/100,000) race/ethnicity, female gender (1,181/100,000), and Medicaid eligibility (2,975/100,000). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
This study projects that the total cost of caring for Americans with Alzheimer's and related dementias will grow enormously over the coming decades, driven by an aging population. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients to estimate whether aducanumab and donanemab were reasonably priced for the health benefit they provide. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
The future price of lecanemab in European countries is unknown. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A collaborative dementia care program demonstrated significant financial benefit in a managed Medicare population. 4 key findings →
Design: cohort Participants: 242 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our review supports that biofluid biomarker testing could be cost-effective to diagnose AD. 2 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our study shows that ICERS of PFA combined with MI and MI alone amounted to €21,443 and €21,543 respectively per improved Z score point compared to the placebo and are below the WTP of €50,000 while the ICER of PFA alone amounted to €111,720 per improved Z score point. 3 key findings →
Participants: 1,525 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
9 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Impact of special care unit for patients with advanced Alzheimer's disease on patients' discomfort and costs
- Lipoprotein lipase: structure, function, regulation, and role in disease
- Predictors of same-admission cholecystectomy in mild, acute, biliary pancreatitis
- The worldwide costs of dementia in 2019
- Medicare spending associated with a dementia diagnosis among older adults
- Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D
- Comprehensive Longitudinal Health Care in the Home for High‐Cost Beneficiaries: A Critical Strategy for Population Health Management
- Advance care planning for nursing home residents with dementia: Influence of 'we DECide' on policy and practice
- Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →